On November 21, 2023, Connect Biopharma Holdings Limited and Simcere Pharmaceutical Co., Ltd. announced an exclusive license and collaboration agreement for the development and commercialization of Connect Biopharma’s rademikibart in Greater China. This partnership marks a significant milestone for both companies in advancing healthcare solutions.
As part of the agreement, Connect Biopharma will receive a substantial upfront payment of ¥150 million RMB (equivalent to US$21 million). Additionally, Connect Biopharma stands to earn up to ¥875 million RMB (equivalent to US$120 million) upon achieving specific development and commercial milestones. Furthermore, Connect Biopharma will receive royalties based on low double-digit percentages of net sales.
Under the terms of the agreement, Simcere has been granted exclusive rights to develop, manufacture, and commercialize rademikibart for all indications in Greater China, including mainland China, Hong Kong, Macau, and Taiwan. Connect Biopharma, on the other hand, will retain rights to the drug in all other markets. This strategic division ensures a focused approach to maximizing the drug’s potential in the respective regions.
Simcere will assume the responsibility of submitting rademikibart’s new drug application for atopic dermatitis in China. Furthermore, Simcere will conduct and bear the costs of all future clinical studies for rademikibart in additional disease indications within Greater China. This collaborative effort will leverage Simcere’s expertise and resources to accelerate the development and availability of rademikibart for patients in the region.
Connect Biopharma will continue to oversee and complete all ongoing China clinical trials for rademikibart, specifically in the field of atopic dermatitis. The company remains on track for a new drug application submission for atopic dermatitis in China by the end of the first quarter of 2024. This dedication to advancing the drug’s development demonstrates Connect Biopharma’s commitment to improving patient outcomes and addressing unmet medical needs.
The exclusive license and collaboration agreement between Connect Biopharma and Simcere represents a significant step forward in the field of biopharmaceuticals. By joining forces, the two companies are poised to make a lasting impact on healthcare in Greater China and beyond.
Connect Biopharma Holdings Limited
Updated on: 04/12/2023
Debt to equity ratio:
Price to earnings ratio:
Price to book ratio:
We did not find social sentiment data for this stock
|Analyst / firm||Rating|
Stock Analysis: CNTBs Impressive Earnings Growth and Potential for Long-Term Success
On November 21, 2023, CNTB stock opened at $2.19, slightly higher than the previous close of $2.14. Throughout the day, the stock’s price fluctuated within a range of $1.28 to $2.23. The trading volume for the day was 170,906 shares, significantly higher than the average volume of 56,427 shares over the past three months. CNTB has a market capitalization of $120.6 million. The company has shown impressive earnings growth over the past year, with a growth rate of 44.63%. The earnings growth for this year stands at 33.26%. The lack of revenue growth data for the previous year suggests that CNTB may be a relatively new or developing company. The P/E ratio and price/sales ratio are not provided, but the price/book ratio is 0.76, suggesting that the stock may be undervalued relative to its book value. CNTB had a negative EPS forecast of -$3.58 for the current quarter and reported zero annual revenue for the previous year, indicating that it may still be in the early stages of generating significant income. The company reported an annual profit of -$118.4 million, suggesting that it has not yet achieved profitability. The lack of information on CNTB’s competitors makes it difficult to assess the company’s competitive position within the industry. Overall, while the stock opened slightly higher than the previous close, it experienced significant price fluctuations throughout the day. The company has shown strong earnings growth in the past, but it is important to consider the lack of revenue growth and negative profitability when evaluating its long-term prospects.
Connect Biopharma Holdings Ltd: Strong Performance, Positive Price Forecasts, and Buy Rating Make it a Promising Investment Opportunity in the Biopharmaceutical Sector
Connect Biopharma Holdings Ltd (CNTB) stock experienced a significant increase in performance on November 21, 2023, according to data from CNN Money. The 1 analyst offering 12-month price forecasts for CNTB has a median target of 7.11, with both the high and low estimates also at 7.11. This median estimate represents a remarkable 377.08% increase from the last recorded price of 1.49.
The consensus among 1 polled investment analyst remains to buy stock in Connect Biopharma Holdings Ltd, and this rating has held steady since October, when it was initially assigned a buy rating. This consistent recommendation indicates that analysts have confidence in the company’s future prospects and believe it to be a good investment opportunity.
Connect Biopharma Holdings Ltd is set to release its earnings report for the current quarter on November 30. As of now, the company has reported negative earnings per share of -$3.58 and no sales for the current quarter.
Connect Biopharma Holdings Ltd is a biopharmaceutical company that focuses on the discovery and development of novel immune modulators for the treatment of autoimmune diseases and cancer. The company’s innovative approach to drug development has garnered attention from analysts, resulting in positive price forecasts and a buy rating.
Investors should keep a close eye on Connect Biopharma Holdings Ltd, as the upcoming earnings report could provide valuable insights into the company’s financial health and future growth prospects. The stock’s strong performance on November 21, 2023, coupled with the positive price forecasts and buy rating, suggests that Connect Biopharma Holdings Ltd may be a promising investment opportunity for those looking to invest in the biopharmaceutical sector.